Uncategorized

10 clinical trials to watch in the second half of 2026

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

​Read More

Published

on

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version